Clinical Trials of Repurposed Antivirals for SARS-CoV-2.Antimicrob Agents Chemother. 2020 Aug 20; 64(9)AA
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.
Links
MeSH
Adenosine MonophosphateAlanineAmidesAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDrug Administration ScheduleDrug CombinationsDrug RepositioningHumansHydroxychloroquineInterferonsLopinavirPandemicsPneumonia, ViralPyrazinesRandomized Controlled Trials as TopicRibavirinRitonavirSARS-CoV-2Survival AnalysisTreatment Outcome
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Review
Language
eng
PubMed ID
32631826
Citation
Martinez, Miguel Angel. "Clinical Trials of Repurposed Antivirals for SARS-CoV-2." Antimicrobial Agents and Chemotherapy, vol. 64, no. 9, 2020.
Martinez MA. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020;64(9).
Martinez, M. A. (2020). Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 64(9). https://doi.org/10.1128/AAC.01101-20
Martinez MA. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020 Aug 20;64(9) PubMed PMID: 32631826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
A1 - Martinez,Miguel Angel,
Y1 - 2020/08/20/
PY - 2020/7/8/pubmed
PY - 2020/9/4/medline
PY - 2020/7/8/entrez
KW - COVID-19
KW - SARS-CoV-2
KW - antivirals
JF - Antimicrobial agents and chemotherapy
JO - Antimicrob Agents Chemother
VL - 64
IS - 9
N2 - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.
SN - 1098-6596
UR - https://www.unboundmedicine.com/medline/citation/32631826/Clinical_Trials_of_Repurposed_Antivirals_for_SARS_CoV_2_
DB - PRIME
DP - Unbound Medicine
ER -